Table 2. Population characteristics and weighted univariate analysis of risk factors associated with premedication use.
| Characteristics (n with available data) | Total (n = 1494) | Weighted univariate analysisa | ||
|---|---|---|---|---|
| Premedication (n = 76) | No premedication (n = 1418) | P-valueb | ||
| Sex No. (%) (n = 1494) | ||||
| Male | 803 (53.7) | 48 (56.1) | 755 (55.3)) | 0.860 |
| Female | 691 (46.3) | 28 (43.9) | 663 (44.7) | |
| GA (weeks) (n = 1494) | ||||
| Mean (SD) | 27.8 (2.2) | 29.7 (2.1) | 28.5 (2.5) | <0.01 |
| Median [IQR] | 28.0 [26.0–29.0] | 30 [28–31] | 28 [27–30] | <0.01 |
| Range | 23–34 | 25–34 | 23–34 | |
| Birth weight (g) (n = 1494) | ||||
| Mean (SD) | 1070 (362) | 1432 (464) | 1167 (430) | < .001 |
| Median [IQR] | 1000 [795–1300] | 1391 [1037–1767] | 1074 [840–1440] | < .001 |
| Range | 370–2610 | 620–2290 | 370–2610 | |
| Mode of delivery “vaginal” (n = 1486), No. (%) | 546 (36.7) | 20 (69.7) | 526 (64.9) | 0.280 |
| Maternal general anesthesia (n = 1448), No. (%) | 217 (15.0) | 7 (7.4) | 210 (15.4) | 0.016 |
| Intrauterine Growth Restriction (n = 1494), No. (%) | 208 (13.9) | 9 (9.7) | 199 (14.5) | 0.136 |
| 1 min Apgar score (n = 1462) | ||||
| Median [IQR] | 6 [3–8] | 8 [6–9] | 6 [3–8] | < .001 |
| Range | 0–10 | 1–10 | 0–10 | |
| Exogenous surfactant in the DR (n = 1467), No (%) | 757 (51.6) | 53 (66.1) | 704 (45.8 | <0.001 |
| Period of birth “Day” (n = 1439), No. (%) | 679 (47.2) | 41 (59.7) | 638 (48.1) | 0.014 |
a All results (except n) are weighted to take into account differences in the sampling process between GA groups.
b Mann-Whitney’s, t-test or chi square tests for comparisons between premedicated and non-premedicated infants.